Abstract
Ruthenium complex NAMI-A [ImH][trans-RuCl(4)(DMSO-S)Im] (Im = imidazole) is a potential chemotherapeutic drug in cancer treatment. Electroporation can be used to facilitate delivery of NAMI-A into cells. Suspension of B16F1 tumour cells from mouse melanoma in NAMI-A solution was exposed to a train of electric pulses. The effect of NAMI-A was determined by examining cell viability in clonogenic test. Our results show that electroporation increases the otherwise scarce in vitro effects of NAMI-A, i.e. reduces cell viability. At the conditions chosen for experiments 90% of cells survived in the presence of 1 microM NAMI-A, whereas in a combined treatment with 1 microM NAMI-A and electroporation only about 10% of cells survived.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Agents / toxicity
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Dimethyl Sulfoxide / analogs & derivatives*
-
Dimethyl Sulfoxide / therapeutic use
-
Dimethyl Sulfoxide / toxicity
-
Electrochemotherapy*
-
Electroporation
-
Melanoma, Experimental / drug therapy*
-
Melanoma, Experimental / pathology*
-
Mice
-
Neoplasm Metastasis / drug therapy
-
Organometallic Compounds / therapeutic use*
-
Organometallic Compounds / toxicity
-
Ruthenium Compounds
Substances
-
Antineoplastic Agents
-
Organometallic Compounds
-
Ruthenium Compounds
-
imidazolium-bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III)
-
Dimethyl Sulfoxide